Business
Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference
AUSTIN, TX and DURHAM, NC, April 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced that company management will present at and participate in one-on-one meetings at the 24th Annual Needham Virtual Healthcare Conference, taking place April 7–10, 202
About this update from Shattuck Labs, Inc.
[{"type":"image","alt":"Shattuck Labs, Inc.","displaySize":"","headline":null,"caption":"Shattuck Labs, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":69,"url":"https://media.zenfs.com/en/globenewswire.com/b5ea3fb4ff3f25592a62a57f48a4f2e8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/o_.4r1lpCFq8StfajNT2qg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk3O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/b5ea3fb4ff3f25592a62a57f48a4f2e8","width":300,"height":69}},"lazy":false},{"type":"text","content":"AUSTIN, TX and DURHAM, NC, April 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors for the treatment of patients with inflammatory and immune-related diseases, today announced that company management will present at and participate in one-on-one meetings at the 24th Annual Needham Virtual Healthcare Conference, taking place April 7–10, 2025.","length":502,"tagName":"p"},{"type":"text","content":"Conference DetailsFormat: Presentation and one-on-one meetingsPresenter: Taylor Schreiber, M.D., Ph.D., Shattuck’s Chief Executive OfficerDate: April 9, 2025Time: 3:00 PM EDTWebcast link: HERE","length":197,"tagName":"p"},{"type":"text","content":"A live webcast of the 24th Annual Needham Virtual Healthcare Conference presentation will be available on the Events and Presentations section of the Company’s website. A replay of the webcast will be archived for up to 30 days following the presentation date.","length":270,"tagName":"p"},{"type":"text","content":"About SL-325SL-325 is a potential first-in-class Death Receptor 3 (DR3) blocking antibody designed to achieve a complete and durable blockade of the clinically validated DR3/TL1A pathway. Shattuck’s preclinical studies demonstrate high affinity binding and superior activity over TL1A antibodies, and offer a data-driven rationale for targeting the TNF receptor, DR3, versus its ligand, TL1A. SL-325 has completed a GLP toxicology study in non-human primates, with an IND filing expected in the third quarter of 2025.","length":518,"tagName":"p"},{"type":"text","content":"About Shattuck Labs, Inc.Shattuck Labs, Inc. (Nasdaq: STTK) is a biotechnology company specializing in the development of potential treat...